Background. Quantitative information about the management of patients with advanced heart failure (HF) is scarce. Objective. To assess the management of primary care patients with HF in their last year of life.
Introduction
Heart failure (HF) is a chronic progressive disease with high morbidity and mortality. 1 The majority of patients have multiple co-morbidities and an uncertain disease trajectory with acute exacerbations. 2 Angiotensinconverting enzyme (ACE) inhibitors [or angiotensin receptor blockers (ARBs) in case of intolerance], betablockers and aldosterone antagonists on top of diuretics are well-established drugs for HF, although evidence is limited to HF with reduced ejection fraction. 1 The cardiovascular treatment and palliative care options in the last phase of life of patients with advanced HF has been underexposed in the literature. 1 Recently, some guidance was published on how to provide palliative care to these patients. 2 Previous practice-based studies that focused on palliative and end-stage care of patients with HF were mostly qualitative in nature. [3] [4] [5] [6] [7] [8] Especially, the perspectives of patients and their relatives and barriers in care encountered by these patients received attention. 6 Planning of the (end-stage) care in HF is hampered by an uncertain disease trajectory. Gradual deterioration in health over months or years is interrupted by occasional acute, often severe, exacerbations with a high risk of death. 9, 10 With progression of the disease, frequent adaptations of medication is needed for symptom management, changes in blood pressure and serum potassium levels and deterioration of the renal function. Physicians have to manoeuvre the patients between the small margins of fluid overload and under-perfusion. 2 Standard HF drugs should in general be continued until the end of life because of their symptoms reducing effects, however, adaptation of the dosages or even stopping is often needed to adapt to decreasing blood pressure and renal function in advanced cases. 2 Studies with quantitative data on the mode and place of death are scarce, but a small study from primary care showed that co-morbidities often coexist and that a substantial number of patients with HF lack a terminal phase, dying suddenly or by coexisting malignancies.
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Data on the management of advanced HF are mainly from hospitalized patients. 12, 13 The care provided in the general practice, however, differs substantially from hospital care because of differences in care facilities and the patient casemix.
14 Patients with HF who are cared for solely by the GP are more often older and have more co-morbidities than those (co)managed by the cardiologist. 14 Because practice-based data on the last year of life of patients with HF are scarce and virtually lacking for the primary care setting, we set out to gather such real life data. We also wanted to compare patients treated in primary care only with those who received (co-)treatment by a cardiologist.
Methods
Patients with a diagnosis of HF were selected from a large central database containing de-identified data from 1992 onwards of all patient encounters of 36 GPs working in 23 general practices centralized in six primary health care centres in the Netherlands. All these general practices, known as the General Practice Network Utrecht (HNU) are affiliated to the Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht and provide health care to a dynamic cohort of roughly 60 000 people. All patient contacts with the GP are recorded in an electronic medical file using a diagnostic code (International Code for Primary Care (ICPC-2). All primary care out of office hours patient contacts and specialist letters with information about hospital admissions and findings from outpatient clinic visits are also copied in the database and labelled with an ICPC-code. Medical specialist in the Netherlands are obliged to write letters to the GPs about their patient contacts. The medical prescriptions are recorded according to the Anatomical Therapeutic Chemical Classification (ATC) standard. All citizens are registered with a GP in the Netherlands, irrespective of treatment of a specialist, including patients living in a home for the elderly, but except for those living in a nursing home or hospice. At the point of time that a patient moves to a nursing home or hospice, the care of the patient and the medical files from the GP's database are handed over to the hospice or nursing home physician. When patients die in the nursing home, hospice or in hospital, GPs receive a notification of death, including the suspected cause of death according to the physician who certified death. GPs provide death certificates of any patient who dies at home or in the home for elderly. Thus, date of death and its suspected cause are always notified of any patient who was enlisted with the GP. In the large majority of our population, mode of death was classified without autopsy.
Patients were eligible for our study when they were labelled with the diagnosis of HF (ICPC-2 code K77) and died between 2001 and 2006. The electronic medical patient files of these patients were scrutinized retrospectively until the date of the first time of diagnosis of HF, which could be well before 2001. The diagnosis of HF could either have been established by the GP or cardiologist.
We excluded eight (2%) patients with missing data because their care and records were completely handed over to the caring physician of the nursing home or hospice during their last year before death.
Place of death and mode of death were deduced from the medical records as were other variables such as co-morbidities, the number of home visits or visits to the home for the elderly, hospital outpatient visits, hospital admissions and drug use during the last year before death.
Data analyses
Dates were used to calculate time intervals: age at the time of diagnosis, age at death and time between diagnosis and death. To compare groups, chi-square test was used for proportions and Student's T-test for continuous variables. Whether there was an association between cardiovascular medication, palliative medication, place of death and mode of death with involvement of a cardiologist in the last year was assessed by multivariable logistic regression analyses, after correction for potentially confounding variables [age, sex, cardiovascular diseases other than HF, diabetes, hypertension, chronic obstructive pulmonary disease (COPD), cancer, anaemia, hospitalization and home visits of the GP in the last year]. 15 We used SPSS 16.0 for statistical analysis.
Results
The mean age of the 399 patients with HF was 78.3 (SD 9.1) years at the time of diagnosis and 82.3 (SD 8.8) years at death and 51.1% were female (see Table  1 ). In men, the diagnosis of HF was at the age of 76.0 years as compared to 80.5 years in women. Both men and women died 4 years after diagnosis. In 259 (64.9%) patients, the diagnosis of HF was established by a cardiologist and in 140 (35.1%) by the GP. In total, 283 (70.7%) patients had ever consulted a cardiologist from the date of diagnosis onwards and exactly 100 (25.1%) patients consulted a cardiologist in the last year of their life.
Patients co-treated by a cardiologist in their last year were 6.2 years younger at death and more often men (59.0 versus 45.5%) than those treated by the GP only (see Table 1 ).
Patients had a mean of 4.7 co-morbid conditions. Especially, COPD (35.1%), anaemia (25.8%) and cancer (29.5%) were common non-cardiac co-morbidities.
Patients used a mean of three different types of HF medication during the last year and nearly all (93%) used diuretics, mainly furosemide (84%). Those cotreated by a cardiologist in their last year used more cardiovascular drugs than those treated by the GP only (see Table 1 ).
The majority of patients died either at home (33.3%) or in the home for the elderly (22.6%), all cared for by the GP. Another 10.5% died outside the hospital; 8% in a nursing home and 2.5% in a hospice. In total, 33% of all patients died in the hospital, after a mean length of stay of 11.3 days. Eventually, 6% of the 399 patients died on the cardiology ward, 7% on the internal ward, 7% on the pulmonary ward and 13% on other wards (see Table 2 ).
In 23.1% of cases, progressive HF was considered the cause of death and in 27.8% sudden cardiac death (including pulmonary embolism). In 49.1%, non-cardiac causes were considered as cause of death, including six patients (1.5%) who died by euthanasia (four of them had co-morbid terminal cancer). See Table 2 .
During the last 12 months of their life, patients were home visited by their GP on average 12.1 (range 0-53) times, and patients visited on average 0.42 times a cardiology outpatient clinic (see Table 3 ). In total, 62% of all patients were admitted to the hospital at least once in their last year.
In the last 3 months of life, 4.8% of all the patients received diuretics intravenously at regular intervals at home or in the nursing home. There were no significant differences in the use of diuretics and palliative drugs between those managed by the GP only as compared to those who were co-treated by a cardiologist (see Table 3 ). One-third (35%) of all patients received opioids during the end stage, in 8% of cases subcutaneously. Seven per cent of patients received oxygen. Almost half of the patients (45%) used benzodiazepines and 7% used a selective serotonine reuptake inhibitor antidepressant drug.
With multivariable analyses, after correction for potential confounders, only the use of ACE inhibitors/ ARBs, aldosterone antagonists and beta-blockers were significantly lower in patients cared for by the GP as compared to those co-treated by the cardiologist (Table 4) .
Subgroup analyses of the patients who died of progressive HF (n = 92) showed that palliative care was about similar to the complete population, however, with somewhat more use of opioids (45.7%). The same was true for the subgroup of patients with comorbid cancer (n = 117), with 46.2% using opioids. Patients with co-morbid cancer died less frequently than the complete population because of sudden cardiac death (15.4%) or progressive HF (17.1%) but more 
Discussion
To the best of our knowledge, this is the first study that presents quantitative data about the last year of life of patients diagnosed with HF, including data of those co-treated by a cardiologist. The workload of these patients lies in primary care with the GP. Although, 71% of the patients ever consulted a cardiologist, only 29% consulted the cardiology outpatient clinic in the last year of life. Patients with HF continue mainstay drugs for HF till the end of life, more so in patients (co)treated by the cardiologist, however, at lower prescription rates than generally recommended in current guidelines. 1 However, at higher rates than in HF patients who were referred to hospice care after recent (within 6 months in 88% of cases) hospitalization for HF. 16 'Typical' palliative drugs were used limited, except for benzodiazepines and opioids, with somewhat higher rates selectively in patients who died of progressive HF and in the subgroup of patients with coexisting cancer. Special cardiac treatment options for end-stage HF, including devices and diuretics intravenously were largely underused in our study population. 12 None of the patients had a left ventricular assist device. Finally, hospice care (2.5%) was provided scarcely. Uncertain illness trajectory with acute exacerbations, sudden death (27.8%), falls for which medical support was needed (30%), multi-morbidity and uncertainty about when the palliative phase initiates in HF are likely causes for inappropriate use of all potentially available treatment and care for these patients. 2, 8 Of notice is that nearly one-third (29.5%) of our population also had cancer. Cancer has in contrast with HF a rather marked terminal phase in which drugs against cancer are stopped and substituted by palliative drugs, and patients with cancer have readily access to palliative care facilities. 17 In our population, however, the subgroup of patients (n = 117) with comorbid cancer did not receive more palliative drugs, hospice care or died at other places than the rest of the patients. Only the mode of death was somewhat different with less sudden death and death because of progressive HF and more often cancer notified as the cause of death.
It is evident that the care of advanced HF is very complex and that HF is often just one of the multiple chronic progressive and disabling diseases in an elderly patient population. In our study, 30% of patients had also COPD, cancer and/or anaemia, and it is imaginable that a substantial number of patients in our study died with HF rather than because of HF. In six cases (1.5%; 4 with co-morbid cancer), euthanasia was the cause of death in our study. Euthanasia is legal in the Netherlands, when performed according to strict rules and reported to the legal authorities.
Strengths and limitations
Strength of our study is that we used longitudinal data of a whole year, the last year of live, of a representative sample of all patients with a diagnosis of HF. The participating six primary health care centres represent different communities (age and socio-economic background) and settings (rural, suburban and urban) and can be considered to represent the Dutch (general practice patient) population. Because every Dutch citizen is legally bound to register with a GP, except for patients living in a nursing home or hospice, information about any patient with a diagnosis of HF could be included in our study. Moreover, because medical specialists are obliged to provide letters to the GP about hospital admissions and outpatient clinic visits of any patient.
Probably, some patients have been misdiagnosed as HF patient in our study. This could especially have occurred in the 140 (35.1%) patients diagnosed by the GP. In the beginning of 2000, it was common practice that GPs diagnosed HF on clinical grounds and the response to treatment. 14, 18 In more recent years, B-type natriuretic peptide measurements were added to the diagnostic assessment. 19 Echocardiography, however, is still underused in primary care. 20 Importantly, the aim of our study was the assessment of care in the last year of a population 'judged' to be suffering from HF by the caring physician. 11 Thus, possible misdiagnosis could not have had a large impact on our results.
Because we used retrospective real-practice data, under-recording of certain items is likely. Especially, 'negative findings' are prone as such. Care provided by HF nurses is certainly underrated in our study because the nurses do not provide letters to the GPs about the patients they care for, while telephone consultations between HF nurses and the GP are likely not always recorded. Although, we lack exact data, we suspect that <10% of our population received care from HF nurses. The network of HF nurses in the Netherlands is far too small, as in the rest of Europe to cover the needs of all patients who possibly profit of their care. 21 The mode of death in our study was based on the recordings of death certificates in the electronic files of the GP. In case of death in hospital, hospice or nursing home, correspondence from the responsible physician was used to classify the mode of death. Only in a few cases, information from autopsy was available. In 6.3% of cases in our study, the cause of death was unknown.
When patients move to a nursing home or hospice permanently, the care and records are usually taken over by a nursing home physician. A situation different from the UK and possibly from other countries in Europe. We therefore could not provide data of HF patients who lived already in a nursing home before their final year of life and also of eight patients (2%) who were referred to a nursing home during their last year before death.
Comparison with existing literature Previous cross-sectional studies of HF patients also showed differences in characteristics of patients managed by GPs only, as compared to those (co-) treated by a cardiologist in respect to age, sex and medication prescribed. 14, 18 In a previous study from primary care with patients labelled with HF, causes of death were similar to our study, with also often (co-morbid) cancer as the cause of death. 11 Compared with the Dutch general population aged >80 years, somewhat more persons in our study died in the hospital (32.6 versus 25%) and at home (33.3 versus 20%) and clearly less died in the home for elderly or nursing home (30.9 versus 55%) (www.cbs.nl). In general, death in the hospital is low in the Netherlands as compared to other European countries. The age of death was high in our study (82.8 years), well above the mean age of death of the Dutch general population (in 2005; 73.0 years for men and 78.7 years for females) (www.cbs.nl). This underlines that HF is primarily a condition of ageing. 1, 9, 22 Quantitative studies suggest that patients' and carers' needs are insufficiently met in advanced HF. 5, 6, 8 In our study, the majority of patients, probably except those suffering from sudden cardiac death, would benefit of a palliative care approach. Although, we cannot provide data about all aspects of palliative care, we could show that the use of palliative drugs was rather low in our study. Since we do not know how patients and care providers rated the adequacy of symptom relieve, we do not know whether the care provided in our study was insufficient. Large variations in individual dying trajectories, often dominated by acute exacerbations with hospital admissions to different specialties, certainly increases the risk of discontinuity and insufficiency of care of patients with advanced HF. 10 Because HF medication does not only reduce morbidity and mortality but also reduce symptoms (such as breathlessness), they are palliative medication in itself. 2 Optimizing the performance of the deteriorating heart ('an engine running out of fuel') by the use of HF medication remains an important palliative treatment goal, however, regular adjustments and titration of HF drugs are needed to prevent hypotension and deterioration of renal function. 1 We do believe with others, that, although GPs are familiar with a holistic approach with management of symptoms and the provision of psychological, social and spiritual support to patient and carers, consultation and coordination of care with cardiologists, HF nurses but also a geriatrician and possibly a palliative care team would probably improve the care of patients with advanced HF. 3, 8, 22, 23 The lack of coordinated care in patients with advanced HF is certainly not unique for the Netherlands but a problem seen in many countries in Europe. 2 The position statement of the Heart Failure Association of the European Society of Cardiology is one of the recently started initiatives that can help to improve the care of HF patients when in the last year of their life. 2 
Implications of our study
The results of our study provide essential input for future studies and for new policies about meeting the growing demands on primary care by the increasing population of patients with HF. Special attention should be paid to the multiple co-morbidities and the frailty commonly present in the elderly patients with HF. Studies in other countries than the Netherlands could complete the picture of the care provided to these patients.
Definitely, more studies are needed that focus on optimizing the management of the elderly patients with HF possibly dying within 1 year.
Conclusion
A minority of patients with advanced HF has a terminal phase ending with death because of progressive HF. Most patients face an uncertain illness trajectory, with multiple possible causes of death and a low input from the cardiologist in the last year. HF drugs and 'typical' palliative drugs are used infrequently. A holistic individualized approach, including the care for co-morbid conditions and tuning of the secondary care with primary care would possibly improve the management of these patients.
